Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab +/- Lenvatinib as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma
NCT05807776Phase 2Completed
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Apr 2023
- Primary completion
- Jul 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in hepatocellular carcinoma (HCC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Started Apr 2023; status: completed.
02
Drugs
tislelizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05807776.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05807776.